Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

The JAK/STAT pathway plays a major role in the pathogenesis of myelofibrosis. JAK inhibitors improve symptoms of myelofibrosis but may cause cytopenias and have modest effects on bone marrow fibrosis. Patients often develop clinical resistance over time, making switching to another JAK inhibitor therapy a promising treatment option. This session will provide an overview of myelofibrosis, outlining its significant clinical burden and how the use of newer agents in more personalized treatment approaches may address myelofibrosis progression and improve outcomes for patients with relapsed/refractory disease. Key managed care considerations, such as treatment selection, sequencing, and cost-effectiveness will be discussed. The discussion will encompass strategies for oncology and managed care professionals to optimize treatment plans, ensuring patients receive appropriate medications, with a focus on managing treatment-related toxicities, minimizing disease progression, and improving quality of life for patients with myelofibrosis.

Target audience: Managed care pharmacists, oncology pharmacists

Type of activity: Application
Release date: April 9, 2025
Expiration date: April 9, 2026

Time to complete activity: 1.5 hours

Learner level: Intermediate

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate between the approved JAK inhibitors based on clinical data and guideline recommendations for use in the treatment of myelofibrosis.
• Explore evidence-based second-line treatment plans for patients with myelofibrosis who have relapsed, are refractory, or have developed intolerance to previous JAK inhibitor therapy.
• Explore managed care strategies that facilitate appropriate treatment and supportive care for patients with myelofibrosis, aimed at improving resource utilization and patient outcomes.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-079-H01-P. The activity is available for CE credit through April 9, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Scott Heinemann, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant: Syndax Pharmaceuticals.

Timothy Mok, PharmD, BCOP, BCPS, has the following financial relationship with a commercial interest to disclose: Consultant: Pfizer.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms